{
    "pmcid": "8248807",
    "qa_pairs": {
        "How can nanobodies enhance their therapeutic potential against different SARS-CoV-2 variants?": [
            "By binding to conserved regions of the spike protein for cross-reactivity",
            "By targeting only the variable regions of the spike protein",
            "By focusing solely on the nucleocapsid protein",
            "By avoiding interaction with the spike protein"
        ],
        "What are the key advantages of nanobodies for therapeutic applications against SARS-CoV-2?": [
            "High stability, solubility, high affinity and specificity, and ease of production",
            "Large size and complex structure",
            "Limited solubility and low specificity",
            "Difficult production in mammalian systems"
        ],
        "What is a potential strategy to enhance the neutralization potency of nanobodies against SARS-CoV-2?": [
            "Combining multiple nanobodies targeting different epitopes on the spike protein",
            "Using a single nanobody with low affinity",
            "Targeting only non-structural proteins",
            "Avoiding the use of cocktail therapies"
        ],
        "What structural study technique is mentioned as crucial for understanding nanobody interactions with the spike protein?": [
            "Cryo-electron microscopy (cryo-EM)",
            "X-ray crystallography",
            "Nuclear magnetic resonance (NMR) spectroscopy",
            "Mass spectrometry"
        ],
        "Which protein is primarily targeted by nanobodies to prevent SARS-CoV-2 entry into host cells?": [
            "The spike protein, particularly its receptor-binding domain (RBD)",
            "The nucleocapsid protein",
            "The envelope protein",
            "The membrane protein"
        ]
    }
}